This suggests that PGC-1α may be a potentially important therapeutic target in the treatment of bone marrow adiposity, bone mineral density loss, osteoporosis, and skeletal muscle aging in postmenopausal women. This evidence concerns the gene PPARGC1A and osteoporosis.